ERBB2 and breast carcinoma: Successful examples include Herceptin (trastuzumab), a humanized monoclonal antibody for targeting HER-2-positive breast cancer [32, 33], and ado-trastuzumab emtansine (T-DM1), a second generation ADC composed of trastuzumab conjugated to maytansoinoid emtansine (DM1).